ClinicalTrials.gg
WithdrawnNCT03377426Updated Oct 26, 2018

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)

A Phase 2 interventional study of LYS228 and Standard of care therapy in Complicated Urinary Tract Infections, sponsored by Novartis Pharmaceuticals. Withdrawn at 5 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-10-26.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Basic science

Why this study was withdrawn
The trial was terminated due to an out-licensing agreement after the new sponsor did not wish to continue the trial

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 274 studies in Urinary Tract Infections with a site in United States — 43 open to participants now, 56 under way, 2 of them phase 3. Urinary Tract Infections · United States.

Enrollment
215th of 224
0 · median 100
Started
2018
with 22 others
Phase 2
31 of 274
2 open now
Registered
141st of 274
by date

Among the 274 studies in Urinary Tract Infections with a site in United States, this one is the 215th largest by enrollment of the 224 interventional ones that give a count, is one of 23 that started in 2018, is one of 31 in phase 2, and was the 141st registered.

Urinary Tract Infections

807 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

43 of the 274 studies in Urinary Tract Infections with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 83 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (28%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 274 studies in Urinary Tract Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate whether LYS228 can be developed for the treatment of complicated urinary tract infections

03

Conditions studied

  • Complicated Urinary Tract Infections

Keywords

  • Urinary tract infection, LYS228, beta-lactam antibiotics, creatinine clearance, Enterobactericeae
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients 18 to 85 years of age with suspected and/or bacteriologically documented complicated UTI judges by the investigator to be serious (required patient to be hospitalized for treatment with intravenous antibiotics)

Exclusion criteria

Exclusion Criteria:

  • Urine Gram stain that demonstrated that a Gram-positive organism was present, or if urine culture results were available, demonstrated Gram- positive organisms were present at ≥10E5 CFU/mL
  • Urine culture result available at enrollment and demonstrating more than 2 different species of microorganisms regardless of the colony count
  • Urine culture result available demonstrating fungal UTI with colony count >10E3 CFU/mL
  • Patient had received prior antibiotics within 72 hours before the initiation of study therapy
  • Patients with estimated \< 30mL/min calculated based in study qualified formula
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    LYS228

    IV infusion

    Drug: LYS228

  • Active comparator
    Standard of care

    IV infusion of standard of care antibiotics for at least 5 days

    Drug: Standard of care therapy

Interventions

  • DrugLYS228

    LYS228 IV infusion

  • DrugStandard of care therapy

    IV infusion of standard of care antibiotics

06

What researchers measure

Primary outcomes

  1. Change from Baseline of the Clinical Response at Day 7

    Clinical success at 7 days after randomization determined by signs and symptoms of infection and the need for additional antibiotics

    Time frame: Baseline, Day 7

  2. Plasma Pharmacokinetics (PK) of LYS228: Area Under the Plasma Concentration-time Curve from time zero to the end of dosing interval tau (AUCtau)

    Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5

    Time frame: Day 5

  3. Plasma Pharmacokinetics (PK) of LYS228: The observed maximum plasma concentration following drug administration (Cmax)

    Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5

    Time frame: Day 5

  4. Plasma Pharmacokinetics (PK) of LYS228: The time to reach the maximum concentration after drug administration (Tmax)

    Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5

    Time frame: Day 5

  5. Plasma Pharmacokinetics (PK) of LYS228: The systemic (or total body) clearance from plasma following intravenous administration (CL)

    Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5

    Time frame: Day 5

  6. Plasma Pharmacokinetics (PK) of LYS228: The volume of distribution at steady state following intravenous administration (Vss)

    Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5

    Time frame: Day 5

  7. Plasma Pharmacokinetics (PK) of LYS228: The terminal elimination half-life (T 1/2)

    Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5

    Time frame: Day 5

  8. Plasma Pharmacokinetics (PK) of LYS228: The amount of time in which the unbound drug concentration exceeds the minimum inhibitory concentration of the organism (%fT>MIC)

    Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5

    Time frame: Day 5

  9. Urine Pharmacokinetics (PK) of LYS228: The amount of drug eliminated in Urine from 0 hours up to 6 hours following intravenus administration (Ae0-6h)

    Calculated based on LYS228 concentration in urine at different time points following drug administration on Day 5

    Time frame: Day 5

  10. Urine Pharmacokinetics (PK) of LYS228: Renal Clearance (CLr)

    Calculated based on LYS228 concentration in urine at different time points following drug administration on Day 5

    Time frame: Day 5

Secondary outcomes

  1. Change from Baseline of the Microbiological Response at Day 7

    Microbiologic success at 7 days after randomization determined by microbial growth in urine culture

    Time frame: Baseline, Day 7

07

Study locations

5 sites
  • Novartis Investigative Site
    Detroit, Michigan 48202, United States
  • Novartis Investigative Site
    Newark, New Jersey 07102, United States
  • Novartis Investigative Site
    Seattle, Washington 98195, United States
  • Novartis Investigative Site
    Odense, 5000, Denmark
  • Novartis Investigative Site
    Athens, 115 27, Greece
08

References and documents

Publications

  • Dean CR, Barkan DT, Bermingham A, Blais J, Casey F, Casarez A, Colvin R, Fuller J, Jones AK, Li C, Lopez S, Metzger LE 4th, Mostafavi M, Prathapam R, Rasper D, Reck F, Ruzin A, Shaul J, Shen X, Simmons RL, Skewes-Cox P, Takeoka KT, Tamrakar P, Uehara T, Wei JR. Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01200-18. doi: 10.1128/AAC.01200-18. Print 2018 Oct. PubMed 30061293 ↗

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2018; primary completion for Oct 2019, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2017
First posted
Dec 19, 2017
StartEst.
Oct 19, 2018
Primary completionEst.
Oct 28, 2019
CompletionEst.
Oct 28, 2019
Last update
Oct 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03377426
Responsible party
Sponsor
First posted
Dec 19, 2017
Start date
Oct 19, 2018 (estimated)
Primary completion
Oct 28, 2019 (estimated)
Completion
Oct 28, 2019 (estimated)
Last update
Oct 26, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion